Fagron, Phytobase Cream, 500 g, Article number: 802156. RX only, For prescription compounding N...
FDA Drug Recall #D-1496-2014 — Class II — July 24, 2014
Recall Summary
| Recall Number | D-1496-2014 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 24, 2014 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Fagron, Inc |
| Location | Saint Paul, MN |
| Product Type | Drugs |
| Quantity | 430 jars |
Product Description
Fagron, Phytobase Cream, 500 g, Article number: 802156. RX only, For prescription compounding Natural self-emulsifying oil-in water vehicle for oil-solvents ingredients. Contains Phytosomes (Plant Oil Bodies), Manufactured by Fagron, Inc. 2400 Pilot Knob Rd, St Paul, MN 55120, NDC 51552-1205-6.
Reason for Recall
Microbial Contamination of Non-Sterile Products: Fagron is recalling six lots due to the presence of mold.
Distribution Pattern
Nationwide and Australia
Lot / Code Information
Lot # 13J30-U17-015413; Exp 10/15 Lot # 13J30-U16-015425; Exp 10/15 Lot # 13I06-U05-014199; Exp 10/15
Other Recalls from Fagron, Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0154-2024 | Class II | NYSTATIN 5BU, Activity (as is): 6482 Units/mg, ... | Dec 11, 2023 |
| D-0156-2024 | Class II | NYSTATIN 2 BU, Activity (as is): 6482 Units/mg,... | Dec 11, 2023 |
| D-0155-2024 | Class II | NYSTATIN 500 MU, Activity (as is): 6482 Units/m... | Dec 11, 2023 |
| D-0157-2024 | Class II | NYSTATIN 150 MU, Activity (as is): 6482 Units/m... | Dec 11, 2023 |
| D-0862-2022 | Class III | Nandrolone Decanoate, USP, 100 g per plastic co... | Mar 4, 2022 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.